Connections Biomind Labs Inc.

Biomind Labs Inc. is a biotechnology research and development company. The Company is focused on transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, the Company is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5- MeO-DMT, and mescaline (collectively, the Molecules), for treating a wide range of therapeutic indications. DMT is a serotonergic psychedelic that exerts its effects through serotonergic receptors in the brain, including 5-HT2A, 5-HT1A, 5-HT2C and 5-HT7 receptors, among others. Under the 5-MeO-DMT Program, it is focused on two drug candidates: the BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and the BMND08: 5-MeO-DMT novel formulation indicated for Alzheimer’s disease. Mescaline is a psychedelic alkaloid of the phenethylamine class.